{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T22:39:24Z","timestamp":1768343964003,"version":"3.49.0"},"reference-count":49,"publisher":"Bentham Science Publishers Ltd.","issue":"5","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["PNT"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Osteoporosis is characterised by a major public health burden, particularly taking into\naccount the ageing global population. Therapeutic modalities for osteoporosis are categorised on\nthe basis of their effect on bone remodeling: antiresorptive and anabolic agents. Anabolic drugs are\nfavoured as they promote the formation of new bone, whereas antiresorptive drugs terminate the\nfurther deterioration of bone. Non-specific delivery of anabolic agents results in prolonged kidney\nexposure causing malignant hypercalcemia, whereas antiresorptive agents and bisphosphonates\nmay produce osteonecrosis of the jaw. Several clinical trials have been reported for combinational\ntherapy of anabolic agents and antiresorptive agents for osteoporosis. However, none of them have\nproven their cumulative effects in the treatment of disease. The present work emphasizes a dualtargeting\ndrug delivery approach comprising of bone anabolic and antiresorptive agents that would\nsimultaneously deliver the therapeutic agents to both the zones of bone. The anticipated pioneering\ndelivery approach will intensify the explicit interaction between the therapeutic agent and bone\nsurfaces separately without developing severe adverse effects and improve osteoporotic therapy\neffectively compared to non-targeted drug delivery.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/2211738510666220902124653","type":"journal-article","created":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T12:45:26Z","timestamp":1662209126000},"page":"384-392","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Dual Targeting Anti-Osteoporotic Therapy Through Potential Nanotherapeutic\nApproaches"],"prefix":"10.2174","volume":"10","author":[{"given":"Sagar","family":"Salave","sequence":"first","affiliation":[{"name":"Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Ahmedabad,\nIndia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dhwani","family":"Rana","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Ahmedabad,\nIndia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derajram","family":"Benival","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Ahmedabad,\nIndia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","year":"2004","unstructured":"WHO scientific group on the assessment of osteoporosis at primary health care level summary meeting report. Available from: 2004"},{"key":"ref=2","author":"Farooki A.","unstructured":"Farooki A.;  Osteoporosis: Key concepts Available from:"},{"key":"ref=3","first-page":"29","volume":"20","author":"Arkusz K.","year":"2018","unstructured":"Arkusz K.; Klekiel T.; Niezgoda N.; B\u0119dzi\u0144ski R.; The influence of osteoporotic bone structures of the pelvic-hip complex on stress distribu-tion under impact load. Acta Bioeng Biomech 2018,20(1),29-38","journal-title":"Acta Bioeng Biomech"},{"key":"ref=4","author":"Curtis S.","year":"2019","unstructured":"Curtis S.;  Types and Causes of Osteoporosis Available from: 2019","journal-title":"Types and Causes of Osteoporosis"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/0002-9343(83)90860-4","volume":"75","author":"Riggs B.L.","year":"1983","unstructured":"Riggs B.L.; Melton L.J.; Evidence for two distinct syndromes of involutional osteoporosis. Am J Med 1983,75(6),899-901","journal-title":"Am J Med"},{"key":"ref=6","year":"2021","unstructured":"Facts and statistics. International Osteoporosis Foundation. Available from:  [cited: February 21, 2021]2021"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.ajog.2005.08.047","volume":"194","author":"Lane N.E.","year":"2006","unstructured":"Lane N.E.; Epidemiology, etiology, and diagnosis of osteoporosis. Am J Obstet Gynecol 2006,194(2),S3-S11","journal-title":"Am J Obstet Gynecol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1136\/pgmj.2007.057505","volume":"83","author":"Blake G.M.","year":"2007","unstructured":"Blake G.M.; Fogelman I.; The role of DXA bone density scans in the diagnosis and treatment of osteoporosis. Postgrad Med J 2007,83(982),509-517","journal-title":"Postgrad Med J"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/00003086-200003000-00016","author":"Lane J.M.","year":"2000","unstructured":"Lane J.M.; Russell L.; Khan S.N.; Osteoporosis. Clin Orthop Relat Res 2000(372),139-150","journal-title":"Clin Orthop Relat Res"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"108252","DOI":"10.1016\/j.celrep.2020.108252","volume":"33","author":"Wei H.","year":"2020","unstructured":"Wei H.; Xu Y.; Wang Y.; Identification of fibroblast activation protein as an osteogenic suppressor and anti-osteoporosis drug target. Cell Rep 2020,33(2),108252","journal-title":"Cell Rep"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"46","DOI":"10.5152\/eurjrheum.2016.048","volume":"4","author":"S\u00f6zen T.","year":"2017","unstructured":"S\u00f6zen T.; \u00d6z\u0131\u015f\u0131k L.; Ba\u015faran N.\u00c7.; An overview and management of osteoporosis. Eur J Rheumatol 2017,4(1),46-56","journal-title":"Eur J Rheumatol"},{"key":"ref=12","first-page":"1017","volume":"19","author":"F\u00f6ger-Samwald U.","year":"2020","unstructured":"F\u00f6ger-Samwald U.; Dovjak P.; Azizi-Semrad U.; Kerschan-Schindl K.; Pietschmann P.; Osteoporosis: Pathophysiology and therapeutic options. EXCLI J 2020,19,1017-1037","journal-title":"EXCLI J"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.3390\/ijms23031393","volume":"23","author":"Tonk C.H.","year":"2022","unstructured":"Tonk C.H.; Shoushrah S.H.; Babczyk P.; Therapeutic treatments for osteoporosis-which combination of pills is the best among the bad? Int J Mol Sci 2022,23(3),1393","journal-title":"Int J Mol Sci"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"Saag K.G.","year":"2017","unstructured":"Saag K.G.; Petersen J.; Brandi M.L.; Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 2017,377(15),1417-1427","journal-title":"N Engl J Med"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1210\/js.2018-00118","volume":"2","author":"Haas A.V.","year":"2018","unstructured":"Haas A.V.; LeBoff M.S.; Osteoanabolic agents for osteoporosis. J Endocr Soc 2018,2(8),922-932","journal-title":"J Endocr Soc"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"142","DOI":"10.2174\/2468187312666211220112324","volume":"11","author":"Salave S.","year":"2021","unstructured":"Salave S.; Rana D.; Benival D.; Peptide functionalised nanocarriers for bone specific delivery of PTH (1-34) in osteoporosis. Curr Nanomed 2021,11(3),142-148","journal-title":"Curr Nanomed"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3390\/ijms20010083","volume":"20","author":"Russow G.","year":"2018","unstructured":"Russow G.; Jahn D.; Appelt J.; M\u00e4rdian S.; Tsitsilonis S.; Keller J.; Anabolic therapies in osteoporosis and bone regeneration. Int J Mol Sci 2018,20(1),83","journal-title":"Int J Mol Sci"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41574-020-00426-5","volume":"17","author":"Estell E.G.","year":"2021","unstructured":"Estell E.G.; Rosen C.J.; Emerging insights into the comparative effectiveness of anabolic therapies for osteoporosis. Nat Rev Endocrinol 2021,17(1),31-46","journal-title":"Nat Rev Endocrinol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1002\/jbmr.1695","volume":"27","author":"Langdahl B.","year":"2012","unstructured":"Langdahl B.; Binkley N.; Bone H.; Odanacatib in the treatment of postmenopausal women with low bone mineral density: Five years of continued therapy in a phase 2 study. J Bone Miner Res 2012,27(11),2251-2258","journal-title":"J Bone Miner Res"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12967-018-1497-4","volume":"16","author":"Lindstr\u00f6m E.","year":"2018","unstructured":"Lindstr\u00f6m E.; Rizoska B.; Henderson I.; Nonclinical and clinical pharmacological characterization of the potent and selective cathepsin K inhibitor MIV-711. J Transl Med 2018,16(1),125","journal-title":"J Transl Med"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.bone.2008.07.242","volume":"43","author":"Mori H.","year":"2008","unstructured":"Mori H.; Tanaka M.; Kayasuga R.; Minodronic acid (ONO-5920\/YM529) prevents decrease in bone mineral density and bone strength, and improves bone microarchitecture in ovariectomized cynomolgus monkeys. Bone 2008,43(5),840-848","journal-title":"Bone"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"770073","DOI":"10.3389\/fphar.2021.770073","volume":"12","author":"Dai Z.","year":"2021","unstructured":"Dai Z.; Fang P.; Yan X.; Single dose of SHR-1222, a sclerostin monoclonal antibody, in healthy men and postmenopausal women with low bone mass: A randomized, double-blind, placebo-controlled, dose-escalation, phase I study. Front Pharmacol 2021,12,770073","journal-title":"Front Pharmacol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s00198-015-3392-7","volume":"27","author":"Cosman F.","year":"2016","unstructured":"Cosman F.; Gilchrist N.; McClung M.; A phase 2 study of MK-5442, a calcium-sensing receptor antagonist, in postmenopausal women with osteoporosis after long-term use of oral bisphosphonates. Osteoporos Int 2016,27(1),377-386","journal-title":"Osteoporos Int"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1002\/jbmr.238","volume":"26","author":"Cosman F.","year":"2011","unstructured":"Cosman F.; Eriksen E.F.; Recknor C.; Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmeno-pausal osteoporosis. J Bone Miner Res 2011,26(3),503-511","journal-title":"J Bone Miner Res"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"717065","DOI":"10.3389\/fphar.2021.717065","volume":"12","author":"Li S.S.","year":"2021","unstructured":"Li S.S.; He S.H.; Xie P.Y.; Recent progresses in the treatment of osteoporosis. Front Pharmacol 2021,12,717065","journal-title":"Front Pharmacol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"904","DOI":"10.2174\/1567201813666161230142123","volume":"14","author":"Gera S.","year":"2017","unstructured":"Gera S.; Sampathi S.; Dodoala S.; Role of nanoparticles in drug delivery and regenerative therapy for bone diseases. Curr Drug Deliv 2017,14(7),904-916","journal-title":"Curr Drug Deliv"},{"key":"ref=27","first-page":"32","author":"Rana D.","year":"2022","unstructured":"Rana D.; Salave S.; Longare S.; Agarwal R.; Kalia K.; Benival D.; Nanotherapeutics in tumour microenvironment for cancer therapy. Nanosci Nanotechnology-Asia 2022,32-47","journal-title":"Nanosci Nanotechnology-Asia"},{"key":"ref=28","doi-asserted-by":"publisher","DOI":"10.2174\/2211738510666220426115340","author":"Salave S.","year":"2022","unstructured":"Salave S.; Rana D.; Pardhe R.; Bule P.; Benival D.; Unravelling micro and nano vesicular system in intranasal drug delivery for epilepsy. Pharm Nanotechnol 2022","journal-title":"Pharm Nanotechnol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.3390\/molecules25092193","volume":"25","author":"Yetisgin A.A.","year":"2020","unstructured":"Yetisgin A.A.; Cetinel S.; Zuvin M.; Kosar A.; Kutlu O.; Therapeutic nanoparticles and their targeted delivery applications. Molecules 2020,25(9),2193","journal-title":"Molecules"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.3390\/ijms18071345","volume":"18","author":"Stapleton M.","year":"2017","unstructured":"Stapleton M.; Sawamoto K.; Alm\u00e9ciga-D\u00edaz C.J.; Development of bone targeting drugs. Int J Mol Sci 2017,18(7),1345","journal-title":"Int J Mol Sci"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/nm.2617","volume":"18","author":"Zhang G.","year":"2012","unstructured":"Zhang G.; Guo B.; Wu H.; A delivery system targeting bone formation surfaces to facilitate RNAi-based anabolic therapy. Nat Med 2012,18(2),307-314","journal-title":"Nat Med"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/nm.3791","volume":"21","author":"Liang C.","year":"2015","unstructured":"Liang C.; Guo B.; Wu H.; Aptamer-functionalized lipid nanoparticles targeting osteoblasts as a novel RNA interference-based bone ana-bolic strategy. Nat Med 2015,21(3),288-294","journal-title":"Nat Med"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"17543","DOI":"10.1021\/jacs.0c07309","volume":"142","author":"Lin X.","year":"2020","unstructured":"Lin X.; Wang Q.; Gu C.; Smart nanosacrificial layer on the bone surface prevents osteoporosis through acid-base neutralization regulated biocascade effects. J Am Chem Soc 2020,142(41),17543-17556","journal-title":"J Am Chem Soc"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"5759","DOI":"10.1021\/acsnano.5b07828","volume":"10","author":"Sun Y.","year":"2016","unstructured":"Sun Y.; Ye X.; Cai M.; Osteoblast-targeting-peptide modified nanoparticle for siRNA\/microRNA delivery. ACS Nano 2016,10(6),5759-5768","journal-title":"ACS Nano"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.bioactmat.2021.09.015","volume":"10","author":"Cui Y.","year":"2021","unstructured":"Cui Y.; Guo Y.; Kong L.; A bone-targeted engineered exosome platform delivering siRNA to treat osteoporosis. Bioact Mater 2021,10,207-221","journal-title":"Bioact Mater"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1080\/10717544.2017.1347966","volume":"24","author":"Xie Y.","year":"2017","unstructured":"Xie Y.; Tan X.; Huang J.; Huang H.; Zou P.; Hu J.; Atorvastatin-loaded micelles with bone-targeted ligand for the treatment of osteoporosis. Drug Deliv 2017,24(1),1067-1076","journal-title":"Drug Deliv"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s00223-011-9485-1","volume":"88","author":"Ponnapakkam T.","year":"2011","unstructured":"Ponnapakkam T.; Katikaneni R.; Miller E.; Monthly administration of a novel PTH-collagen binding domain fusion protein is anabolic in mice. Calcif Tissue Int 2011,88(6),511-520","journal-title":"Calcif Tissue Int"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1211\/jpp.58.1.0002","volume":"58","author":"Jadhav S.B.","year":"2006","unstructured":"Jadhav S.B.; Jain G.K.; Statins and osteoporosis: New role for old drugs. J Pharm Pharmacol 2006,58(1),3-18","journal-title":"J Pharm Pharmacol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.bmcl.2008.12.051","volume":"19","author":"Neale J.R.","year":"2009","unstructured":"Neale J.R.; Richter N.B.; Merten K.E.; Bone selective effect of an estradiol conjugate with a novel tetracycline-derived bone-targeting agent. Bioorg Med Chem Lett 2009,19(3),680-683","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1186\/s12951-021-00976-4","volume":"19","author":"Guo Y.","year":"2021","unstructured":"Guo Y.; Liu Y.; Shi C.; Remote-controllable bone-targeted delivery of estradiol for the treatment of ovariectomy-induced osteoporosis in rats. J Nanobiotechnology 2021,19(1),248","journal-title":"J Nanobiotechnology"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"4907","DOI":"10.1021\/acsabm.1c00199","volume":"4","author":"Jing C.","year":"2021","unstructured":"Jing C.; Li B.; Tan H.; Alendronate-decorated nanoparticles as bone-targeted alendronate carriers for potential osteoporosis treatment. ACS Appl Bio Mater 2021,4(6),4907-4916","journal-title":"ACS Appl Bio Mater"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.jconrel.2016.04.025","volume":"232","author":"Ryu T.K.","year":"2016","unstructured":"Ryu T.K.; Kang R.H.; Jeong K.Y.; Bone-targeted delivery of nanodiamond-based drug carriers conjugated with alendronate for potential osteoporosis treatment. J Control Release 2016,232,152-160","journal-title":"J Control Release"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1021\/mp800003u","volume":"5","author":"Pan H.","year":"2008","unstructured":"Pan H.; Sima M.; Kopeckov\u00e1 P.; Biodistribution and pharmacokinetic studies of bone-targeting N-(2-hydroxypropyl)methacrylamide copolymer-alendronate conjugates. Mol Pharm 2008,5(4),548-558","journal-title":"Mol Pharm"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"102153","DOI":"10.1016\/j.nano.2020.102153","volume":"24","author":"Kotak D.J.","year":"2020","unstructured":"Kotak D.J.; Devarajan P.V.; Bone targeted delivery of salmon calcitonin hydroxyapatite nanoparticles for sublingual osteoporosis therapy (SLOT). Nanomedicine 2020,24,102153","journal-title":"Nanomedicine"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"7469","DOI":"10.2147\/IJN.S139775","volume":"12","author":"Cai M.","year":"2017","unstructured":"Cai M.; Yang L.; Zhang S.; Liu J.; Sun Y.; Wang X.; A bone-resorption surface-targeting nanoparticle to deliver anti-miR214 for osteoporosis therapy. Int J Nanomedicine 2017,12,7469-7482","journal-title":"Int J Nanomedicine"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s11914-020-00620-4","volume":"18","author":"Sawamoto K.","year":"2020","unstructured":"Sawamoto K.; \u00c1lvarez J.V.; Herre\u00f1o A.M.; Bone-specific drug delivery for osteoporosis and rare skeletal disorders. Curr Osteoporos Rep 2020,18(5),515-525","journal-title":"Curr Osteoporos Rep"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.jconrel.2011.10.001","volume":"161","author":"Luhmann T.","year":"2012","unstructured":"Luhmann T.; Germershaus O.; Groll J.; Meinel L.; Bone targeting for the treatment of osteoporosis. J Control Release 2012,161(2),198-213","journal-title":"J Control Release"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"4450","DOI":"10.1016\/j.biomaterials.2011.02.059","volume":"32","author":"Segal E.","year":"2011","unstructured":"Segal E.; Pan H.; Benayoun L.; Enhanced anti-tumor activity and safety profile of targeted nano-scaled HPMA copolymer-alendronate-TNP-470 conjugate in the treatment of bone malignances. Biomaterials 2011,32(19),4450-4463","journal-title":"Biomaterials"},{"key":"ref=49","doi-asserted-by":"crossref","first-page":"7450","DOI":"10.1016\/j.bmcl.2010.10.023","volume":"20","author":"Nasim S.","unstructured":"Nasim S.; Vartak A.P.; Pierce W.M.; Taylor K.G.; Smith N.; Crooks P.A.; 3-O-phosphate ester conjugates of 17-\u03b2-O-{1-[2-carboxy-(2-hydroxy-4-methoxy-3-carboxamido)anilido]ethyl}1,3,5(10)-estratriene as novel bone-targeting agents. Bioorg Med Chem Lett ,20(24),7450-7453","journal-title":"Bioorg Med Chem Lett"}],"container-title":["Pharmaceutical Nanotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/2211738510666220902124653","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/208461\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/2211738510666220902124653","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T03:36:56Z","timestamp":1692934616000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/208461\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/2211738510666220902124653","relation":{},"ISSN":["2211-7385"],"issn-type":[{"value":"2211-7385","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-03-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-14","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}